Cancer immunotherapy company Achilles Therapeutics Ltd. raised £100m ($121m) in its Series B round. RA Capital led and was joined by founding investor Syncona and first-time buyers Forbion, Invus, Perceptive Advisors, and Redmile Group. Funds will support two human proof-of-concept studies with a personalized T-cell therapy targeting clonal neoantigens for melanoma and non-small cell lung cancer.
Amphivena Therapeutics Inc. raised $62m through its Series C round that was co-led by NanoDimension and Qiming Venture Partners USA, and included first-time buyers Clough Capital, Aju IB, Korys Merieux, Kaitai Capital, Industrial Investors, and Nawton Limited. Returning backers MPM Capital, funds managed by Tekla Capital Management, and Franklin Berger also participated
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?